A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses (SAD/MAD) Study Following Oral Administration in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699
Latest Information Update: 04 Nov 2021
At a glance
- Drugs YG 1699 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Youngene Therapeutics
Most Recent Events
- 07 Jan 2021 Status changed from recruiting to completed.
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 27 Feb 2020 Planned End Date changed from 29 Feb 2020 to 1 Jun 2020.